Severe acute respiratory syndrome coronavirus 2 structural protein (SARS-CoV-2 structural protein)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structural proteins are four main gene products forming the core architecture of the virus particle: spike glycoprotein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N)[1][3][4][5][6]. The S (spike) protein is responsible for binding host cell receptors (notably ACE2) and mediating membrane fusion, making it the primary determinant of virus entry, tissue tropism, and immune recognition[1][2][4][7]. The M protein organizes virion assembly at the endoplasmic reticulum-Golgi interface and coordinates incorporation of other components. The E protein forms ion channels and plays a minor but crucial role in virus assembly, budding, and virulence. The N protein binds viral RNA for encapsidation and modulates host immune responses[1][3][4][5][6]. Structural proteins are differentiable from the viral non-structural and accessory proteins that primarily mediate RNA synthesis and immune evasion. Therapeutic strategies primarily target the spike protein (via neutralizing antibodies, small molecules, or vaccines), but structural proteins as a whole are essential for virus infectivity and immunogenicity, and some (esp. S and N) are under strong positive selection due to immune pressure and adaptation[7]. The target "Severe acute respiratory syndrome coronavirus 2 structural proteins" is too broad for most structured drug discovery workflows, as each protein (S, N, M, E) has distinct roles, biology, and therapeutic implications; usually, they are considered individually (e.g., "SARS-CoV-2 spike glycoprotein" as a target)[1][2][4][5][6]. Thus, for database purposes, this canonical name and group should be split by protein. Note: - This entry is problematic for structured targeting because it aggregates a protein family rather than a single molecule. - For actual therapeutic targeting, each component (especially spike, but sometimes nucleocapsid or envelope) should be handled as a separate target entity, each with distinct druggable features, biological roles, and clinical relevance[1][2][5].

Other names

SARS-CoV-2 S proteinN proteinM proteinE proteinSARS-CoV-2 spike glycoproteinnucleocapsid proteinmembrane proteinenvelope protein